Page last updated: 2024-12-10

aplaviroc

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3001322
CHEMBL ID1668019
CHEMBL ID1255794
SCHEMBL ID4577096
MeSH IDM0483464

Synonyms (53)

Synonym
4-(4-(((r)-1-butyl-3-((r)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid hydrochloride
bdbm50336345
gw 873140
gtpl805
4-[4-[[(3r)-1-butyl-3-[(r)-cyclohexyl-hydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid
gw-873140
benzoic acid, 4-[4-[[1-butyl-3-[(r)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- & soluble cd4
aplaviroc
benzoic acid, 4-[4-[[1-butyl-3-[(r)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-
gw873140
ak602
461443-59-4
4-[4-[[(9r)-11-butyl-9-[(r)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid
ak 602
gsk873140
ak-602
ono-4128
CHEMBL1668019 ,
NCGC00247933-01
unii-98b425p30v
aplaviroc [inn]
98b425p30v ,
ono 4128
benzoic acid, 4-(4-(((3r)-1-butyl-3-((r)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9-triazaspiro(55)undec-9-yl)methyl)phenoxy)-
CHEMBL1255794
gsk-873140
2g12 antibody-aplaviroc conjugate
mab pg16-apl conjugate
b12 antibody-aplaviroc conjugate
cd4-igg-apl conjugate
trastuzumab antibody conjugated with aplaviroc
mab b12-apl conjugate
pg9-apl conjugate
trastuzumab-aplaviroc conjugate
cd4-igg aplaviroc conjugate
mab pg9-aplaviroc conjugate
mab 2g12-apl conjugate
pg16 antibody-aplaviroc conjugate
aplaviroc [mi]
aplaviroc [who-dd]
DTXSID6047317
SCHEMBL4577096
AC-31372
674782-28-6
HY-17450
BCP22462
CS-0008289
Q4779956
DB06497
A13471
4-[4-[[(3r)-1-butyl-3-[(r)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid
BA166505
AKOS040741156

Research Excerpts

Overview

Aplaviroc is a novel CCR5 antagonist. It is under investigation as viral entry inhibitors for the treatment of human immunodeficiency virus infection.

ExcerptReferenceRelevance
"Aplaviroc is a novel CCR5 antagonist, a class of compounds under investigation as viral entry inhibitors for the treatment of human immunodeficiency virus infection. "( Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Adkison, KK; Berrey, MM; Bertino, JS; Borland, J; Fang, L; Johnson, BM; Lou, Y; Nafziger, AN; Piscitelli, SC; Song, IH, 2006
)
2.03

Toxicity

ExcerptReferenceRelevance
" Single and repeat doses of 50 mg to 800 mg were well tolerated, with no serious adverse events and no grade 3 or 4 adverse events."( Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
Adkison, KK; Berrey, MM; Fang, L; Lou, Y; O'Mara, K; Piscitelli, SC; Shachoy-Clark, A, 2005
)
0.33
" The most common adverse events were grade 1 gastrointestinal complaints that generally resolved within 1-3 days on therapy."( Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Adkison, K; Berrey, M; Davey, R; Demarest, J; Kumar, P; Lalezari, J; Lou, Y; Patterson, K; Piliero, P; Piscitelli, S; Shachoy-Clark, A; Thompson, M, 2005
)
0.33
" Finally, the third CCR5 antagonist vicriviroc also showed long-term potent viral activity in phase II studies as long as it was boosted with low-dose ritonavir, with no significant differences in grade 3 and grade 4 adverse effects compared to placebo."( CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp, JM; Rockstroh, JK, 2007
)
0.34
" Common clinical adverse events (AEs) were diarrhoea, nausea, fatigue and headache."( Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Bonny, T; Clumeck, N; Currier, J; Kleim, JP; Lazzarin, A; McCarty, D; Millard, J; Slims, J; Sloan, L; Steel, H, 2008
)
0.63
" Common clinical adverse events (AEs) were diarrhoea, nausea, fatigue and headache."( Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Adkison, KK; Berger, D; Bonny, T; Cimoch, P; Lamarca, A; Lazzarin, A; Madison, SJ; McCarty, D; Millard, J; Nichols, WG; Salvato, P; Smaill, FM; Teofilo, E; Yeni, P, 2009
)
0.63

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic and safety profile supports the continued investigation of 873140 with HIV-infected subjects."( Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
Adkison, KK; Berrey, MM; Fang, L; Lou, Y; O'Mara, K; Piscitelli, SC; Shachoy-Clark, A, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"A total of 191 patients were randomized 2:2:2:1 to one of three APL dosing regimens or to lamivudine (3TC)/zidovudine (ZDV) twice daily (bid), each in combination with lopinavir/ritonavir (LPV/r) 400 mg/100 mg bid."( Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Adkison, KK; Berger, D; Bonny, T; Cimoch, P; Lamarca, A; Lazzarin, A; Madison, SJ; McCarty, D; Millard, J; Nichols, WG; Salvato, P; Smaill, FM; Teofilo, E; Yeni, P, 2009
)
0.63

Dosage Studied

ExcerptRelevanceReference
"One hundred and forty-seven patients were randomized 2:2:1 to one of two APL dosing regimens or efavirenz (EFV)."( Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Bonny, T; Clumeck, N; Currier, J; Kleim, JP; Lazzarin, A; McCarty, D; Millard, J; Slims, J; Sloan, L; Steel, H, 2008
)
0.63
" In addition to the hepatic findings, there was an apparent dose-response relationship in the incidence of diarrhoea."( Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Bonny, T; Clumeck, N; Currier, J; Kleim, JP; Lazzarin, A; McCarty, D; Millard, J; Slims, J; Sloan, L; Steel, H, 2008
)
0.63
"A total of 191 patients were randomized 2:2:2:1 to one of three APL dosing regimens or to lamivudine (3TC)/zidovudine (ZDV) twice daily (bid), each in combination with lopinavir/ritonavir (LPV/r) 400 mg/100 mg bid."( Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Adkison, KK; Berger, D; Bonny, T; Cimoch, P; Lamarca, A; Lazzarin, A; Madison, SJ; McCarty, D; Millard, J; Nichols, WG; Salvato, P; Smaill, FM; Teofilo, E; Yeni, P, 2009
)
0.63
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 5Mus musculus (house mouse)IC50 (µMol)0.00040.00030.00170.0052AID1353545
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 5Homo sapiens (human)Kd0.00300.00300.01400.0250AID707904
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID518942AUC (0 to 24 hrs) in Human immunodeficiency virus 1 infected human at 400 mg/kg, BID2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID518941AUC (0 to 24 hrs) in Human immunodeficiency virus 1 infected human at 200 mg/kg, BID2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID518938Hepatotoxicity in monkey assessed as increase in liver ALT level at 2000 mg/kg/day2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID518937Hepatotoxicity in rat assessed as increase in liver ALT level at >500 mg/kg/day2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID518945Hepatotoxicity in rat assessed as increase in liver bilirubin level at >500 mg/kg/day2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID707908Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID554062Antiviral activity against maraviroc-resistant HIV1 isolate CC185 at 10 times IC90 concentration2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID518939AUC (0 to 24 hrs) in Human immunodeficiency virus 1 infected human at 600 mg/kg, BID2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID707912Antiviral activity against R5 tropic Human immunodeficiency virus 12012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID707913Oral bioavailability in monkey2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID518944Half life in healthy human at 200 to 800 mg/kg, BID2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID518940AUC (0 to 24 hrs) in Human immunodeficiency virus 1 infected human at 800 mg/kg, BID2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID518936Antiviral activity against Human immunodeficiency virus 1 infected in human assessed as log reduction in HIV-1 RNA level at 600 mg/kg, BID after 10 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID554063Antiviral activity against maraviroc-resistant HIV1 isolate CC185 at IC90 concentration2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID554061Antiviral activity against maraviroc-resistant HIV1 isolate CC185 at 100 times IC90 concentration2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2
AID518943AUC (0 to 24 hrs) in Human immunodeficiency virus 1 infected human at 800 mg/kg, QD2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1353545Displacement of [125I]-RANTES from CCR5 in mouse NIH/3T3 cells after 1 hr2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent updates for designing CCR5 antagonists as anti-retroviral agents.
AID707904Binding affinity to CCR52012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID1346815Human CCR5 (Chemokine receptors)2006The Journal of biological chemistry, May-05, Volume: 281, Issue:18
Structural and molecular interactions of CCR5 inhibitors with CCR5.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's26 (68.42)29.6817
2010's12 (31.58)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.79 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (21.05%)5.53%
Reviews8 (21.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (57.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus [NCT00197145]Phase 324 participants (Actual)Interventional2005-07-21Terminated
A Phase II, Double-Blind RAndomized, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of GW873130 for 10 Days in HIV-1 Infected Adults [NCT00076284]Phase 220 participants Interventional2004-01-31Completed
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus [NCT00197197]Phase 318 participants (Actual)Interventional2005-07-31Terminated(stopped due to The study was terminated due to hepatoxicity of compound)
A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observat [NCT00123890]Phase 30 participants (Actual)Interventional2005-06-30Terminated(stopped due to The study was terminated due to hepatoxicity of compound)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus [NCT00297076]Phase 3406 participants Interventional2005-07-31Terminated
A PhaseIIb, 96 Week, Randomised, Partially Double-blinded, Multicentre, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of GW873140 in Combination With COMBIVIR (Lamivudine and Zidovudine) Upon Selected Immu [NCT00104429]Phase 2125 participants Interventional2005-01-31Terminated
A Phase IIb, 96 Week, Randomized, Open-label Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra (Lopinavir and Ritonavir) in [NCT00102778]Phase 2175 participants Interventional2004-12-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00197145 (31) [back to overview]Average Area Under the Curve Minus Baseline (AAUCMB) of Plasma HIV-1 RNA Through the Entire Study Period
NCT00197145 (31) [back to overview]Number of Participants With Development of Antiretroviral Resistance to GW873140 400 mg BID and Other Antiretroviral Drugs
NCT00197145 (31) [back to overview]Number of Participants With Plasma HIV-1 RNA <400 Copies Per Milliliter (Copies /mL) at Week 24 and 48
NCT00197145 (31) [back to overview]Number of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 24 and 48
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameter of Albumin During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameter of Albumin During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameter of Creatinine and Total Bilirubin During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameter of Creatinine and Total Bilirubin During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameter of Lipase During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameter of Lipase During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameters of ALT, ALP, AST and CK During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameters of ALT, ALP, AST and CK During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameters of CO2 Content/Bicarbonate, Chloride, Cholesterol, Glucose, High DL Cholesterol, LDL Cholesterol, Triglycerides, Potassium, Urea and Sodium During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Chemistry Parameters of CO2 Content/Bicarbonate, Chloride, Cholesterol, Glucose, High DL Cholesterol, LDL Cholesterol, Triglycerides, Potassium, Urea and Sodium During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in ECG Parameter of RR Interval, Uncorrected QT Interval, QTc Interval (Fridericia), QTc Interval (Bazette), PR Interval and QRS Duration During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in ECG Parameter of RR Interval, Uncorrected QT Interval, QTc Interval (Fridericia), QTc Interval (Bazette), PR Interval and QRS Duration During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Electrocardiograph (ECG) Parameter of Heart Rate (HR) During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Electrocardiograph (ECG) Parameter of Heart Rate (HR) During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameter of Hematocrit During the Randomized Treatment Phase.
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameter of Hematocrit During the Randomized Treatment Phase.
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameter of Hemoglobin During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameter of Hemoglobin During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameter of Mean Corpuscle Volume (MCV) During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameter of Mean Corpuscle Volume (MCV) During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, White Blood Cell (WBC) Count During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Change From Baseline in Haematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, White Blood Cell (WBC) Count During the Randomized Treatment Phase
NCT00197145 (31) [back to overview]Number of Participants With 50% Inhibitory Concentration (IC50) Fold Resistance at Baseline
NCT00197145 (31) [back to overview]Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE), Death, Drug-related AE and AE Leading to Treatment Discontinuation
NCT00197145 (31) [back to overview]Number of Participants With Treatment Emergent Laboratory Abnormalities for Chemistry Data at Any Visit Post-Baseline

Average Area Under the Curve Minus Baseline (AAUCMB) of Plasma HIV-1 RNA Through the Entire Study Period

The area under the plasma HIV-1 RNA curve (AUC) was computed using the trapezoidal rule for all assessments (scheduled and unscheduled) at their actual time points. Baseline was defined as the mean of the Baseline (Day 1) and pre-treatment visit values. Participants without a Baseline assessment was removed from the analysis. The AAUCMB was computed by the AUC divided by the duration of the profile (i.e., the number of days on randomized therapy) minus the Baseline measurement. Data is reported up to Week 40 only due to early termination of the study. (NCT00197145)
Timeframe: Up to Week 40

InterventionLog10 copies/mL (Mean)
APL + OBT-2.03
Placebo + OBT-1.14

[back to top]

Number of Participants With Development of Antiretroviral Resistance to GW873140 400 mg BID and Other Antiretroviral Drugs

Assessment for the development of antiretroviral resistance was performed at each visit up to Follow-up. The genotypic analysis of viral resistance associated mutations was done using protease and reverse transcriptase enzymes. The number of participants with treatment emergent changes in reverse transcriptase and protease genotypic mutations were reported. (NCT00197145)
Timeframe: Up to Follow-up (Week 52)

InterventionParticipants (Count of Participants)
APL + OBT2
Placebo + OBT1

[back to top]

Number of Participants With Plasma HIV-1 RNA <400 Copies Per Milliliter (Copies /mL) at Week 24 and 48

Assessment for plasma HIV-1 RNA was done at Week 24 and also planned at Week 48 by polymerase chain reaction (PCR) analysis. Data is reported for number of participants with plasma HIV-1 RNA <400 copies/mL at Week 24. Data was not collected for Week 48 due to early termination of the study. (NCT00197145)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
APL + OBT5
Placebo + OBT0

[back to top]

Number of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 24 and 48

Assessment for plasma HIV-1 RNA was done at Week 24 and also planned at Week 48 by PCR analysis. Data is reported for number of participants with plasma HIV-1 RNA <50 copies/mL at Week 24. Data was not collected for Week 48 due to early termination of the study. (NCT00197145)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
APL + OBT5
Placebo + OBT0

[back to top]

Change From Baseline in Chemistry Parameter of Albumin During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionGram (g)/L (Mean)
Week 12
Placebo + OBT3.750

[back to top]

Change From Baseline in Chemistry Parameter of Albumin During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionGram (g)/L (Mean)
Week 12Week 24
APL + OBT1.3852.000

[back to top]

Change From Baseline in Chemistry Parameter of Creatinine and Total Bilirubin During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionMicromole (UMOL)/L (Mean)
Creatinine, Week 12Total Bilirubin, Week 12
Placebo + OBT13.000-0.500

[back to top]

Change From Baseline in Chemistry Parameter of Creatinine and Total Bilirubin During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionMicromole (UMOL)/L (Mean)
Creatinine, Week 12Creatinine, Week 24Total Bilirubin, Week 12Total Bilirubin, Week 24
APL + OBT-1.385-2.7140.7698.286

[back to top]

Change From Baseline in Chemistry Parameter of Lipase During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionU/L (Mean)
Week 12
Placebo + OBT0.000

[back to top]

Change From Baseline in Chemistry Parameter of Lipase During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionU/L (Mean)
Week 12Week 24
APL + OBT6.63612.571

[back to top]

Change From Baseline in Chemistry Parameters of ALT, ALP, AST and CK During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionInternational unit per liter (IU/L) (Mean)
ALT, Week 12ALP, Week 12AST, Week 12CK, Week 12
Placebo + OBT9.25025.7504.75037.250

[back to top]

Change From Baseline in Chemistry Parameters of ALT, ALP, AST and CK During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionInternational unit per liter (IU/L) (Mean)
ALT, Week 12ALT, Week 24ALP, Week 12ALP, Week 24AST, Week 12AST, Week 24CK, Week 12CK, Week 24
APL + OBT-7.231-5.429-7.154-3.571-4.231-3.857-3.462102.714

[back to top]

Change From Baseline in Chemistry Parameters of CO2 Content/Bicarbonate, Chloride, Cholesterol, Glucose, High DL Cholesterol, LDL Cholesterol, Triglycerides, Potassium, Urea and Sodium During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionMillimole (MMOL)/L (Mean)
CO2 content/bicarbonate, Week 12Chloride, Week 12Cholesterol, Week 12Glucose, Week 12HDL, Week 12LDL, Week 12Potassium, Week 12Sodium, Week 12Triglycerides, Week 12Urea, Week 12
Placebo + OBT-1.250-2.500-0.7001.150-0.100-0.500-0.225-2.500-0.2400.375

[back to top]

Change From Baseline in Chemistry Parameters of CO2 Content/Bicarbonate, Chloride, Cholesterol, Glucose, High DL Cholesterol, LDL Cholesterol, Triglycerides, Potassium, Urea and Sodium During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionMillimole (MMOL)/L (Mean)
CO2 content/bicarbonate, Week 12CO2 content/bicarbonate, Week 24Chloride, Week 12Chloride, Week 24Cholesterol, Week 12Cholesterol, Week 24Glucose, Week 12Glucose, Week 24HDL, Week 12HDL, Week 24LDL, Week 12LDL, Week 24Potassium, Week 12Potassium, Week 24Sodium, Week 12Sodium, Week 24Triglycerides, Week 12Triglycerides, Week 24Urea, Week 12Urea, Week 24
APL + OBT0.1542.4290.4620.857-0.200-0.5390.415-0.357-0.0360.026-0.552-0.5970.038-0.114-0.8460.7141.1940.071-0.162-0.343

[back to top]

Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts During the Randomized Treatment Phase

The CD4 cell count is an indication of the strength of the immune system. The assessment of CD4 cell count was done by flow cytometry. Baseline was defined as the mean of the Baseline (Day 1) and pre-treatment visit values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12, 24 and 40) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12, Week 24 and Week 40

InterventionCells/Cubic millimeter (mm^3) (Mean)
Week 12
Placebo + OBT80.500

[back to top]

Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts During the Randomized Treatment Phase

The CD4 cell count is an indication of the strength of the immune system. The assessment of CD4 cell count was done by flow cytometry. Baseline was defined as the mean of the Baseline (Day 1) and pre-treatment visit values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12, 24 and 40) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12, Week 24 and Week 40

InterventionCells/Cubic millimeter (mm^3) (Mean)
Week 12Week 24Week 40
APL + OBT55.90927.000153.000

[back to top]

Change From Baseline in ECG Parameter of RR Interval, Uncorrected QT Interval, QTc Interval (Fridericia), QTc Interval (Bazette), PR Interval and QRS Duration During the Randomized Treatment Phase

12-lead ECG assessments were obtained at Day 1 (triplicate measurements), Week 4 and Week 24. The assessments were done using an ECG machine that automatically measured RR, PR, QRS, uncorrected QT, QTc (Bazette) and QTc (Fridericia) intervals. Baseline was defined as the mean of the triplicate assessment done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 4 and Week 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 4 and Week 24

InterventionMillisecond (msec) (Mean)
RR Interval, Week 4RR Interval, Week 24Uncorrected QT Interval, Week 4Uncorrected QT Interval, Week 24QTc Interval (Fridericia), Week 4QTc Interval (Fridericia), Week 24QTc Interval (Bazette), Week 4QTc Interval (Bazette), Week 24PR Interval, Week 4PR Interval, Week 24QRS Duration, Week 4QRS Duration, Week 24
APL + OBT-69.852.2-18.32.5-9.3-5.2-4.5-8.8-8.22.53.2-1.3

[back to top]

Change From Baseline in ECG Parameter of RR Interval, Uncorrected QT Interval, QTc Interval (Fridericia), QTc Interval (Bazette), PR Interval and QRS Duration During the Randomized Treatment Phase

12-lead ECG assessments were obtained at Day 1 (triplicate measurements), Week 4 and Week 24. The assessments were done using an ECG machine that automatically measured RR, PR, QRS, uncorrected QT, QTc (Bazette) and QTc (Fridericia) intervals. Baseline was defined as the mean of the triplicate assessment done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 4 and Week 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 4 and Week 24

InterventionMillisecond (msec) (Mean)
RR Interval, Week 4Uncorrected QT Interval, Week 4QTc Interval (Fridericia), Week 4QTc Interval (Bazette), Week 4PR Interval, Week 4QRS Duration, Week 4
Placebo + OBT-52.11.210.215.40.20.4

[back to top]

Change From Baseline in Electrocardiograph (ECG) Parameter of Heart Rate (HR) During the Randomized Treatment Phase

12-lead ECG assessments were obtained at Day 1 (triplicate measurements), Week 4 and Week 24. The assessments were done using an ECG machine that automatically calculated the heart rate. Baseline was defined as the mean of the triplicate assessment done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 4 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 4 and Week 24

InterventionBeats per minute (Bpm) (Mean)
Week 4
Placebo + OBT4.3

[back to top]

Change From Baseline in Electrocardiograph (ECG) Parameter of Heart Rate (HR) During the Randomized Treatment Phase

12-lead ECG assessments were obtained at Day 1 (triplicate measurements), Week 4 and Week 24. The assessments were done using an ECG machine that automatically calculated the heart rate. Baseline was defined as the mean of the triplicate assessment done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 4 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 4 and Week 24

InterventionBeats per minute (Bpm) (Mean)
Week 4Week 24
APL + OBT5.6-3.9

[back to top]

Change From Baseline in Haematology Parameter of Hematocrit During the Randomized Treatment Phase.

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionPercentage of red blood cells (Mean)
Week 12
Placebo + OBT0.026

[back to top]

Change From Baseline in Haematology Parameter of Hematocrit During the Randomized Treatment Phase.

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionPercentage of red blood cells (Mean)
Week 12Week 24
APL + OBT0.010-0.022

[back to top]

Change From Baseline in Haematology Parameter of Hemoglobin During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

Interventiong/L (Mean)
Week 12
Placebo + OBT6.500

[back to top]

Change From Baseline in Haematology Parameter of Hemoglobin During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

Interventiong/L (Mean)
Week 12Week 24
APL + OBT4.923-4.000

[back to top]

Change From Baseline in Haematology Parameter of Mean Corpuscle Volume (MCV) During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionFemtoliter (FL) (Mean)
Week 12
Placebo + OBT-1.500

[back to top]

Change From Baseline in Haematology Parameter of Mean Corpuscle Volume (MCV) During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionFemtoliter (FL) (Mean)
Week 12Week 24
APL + OBT-3.000-3.429

[back to top]

Change From Baseline in Haematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, White Blood Cell (WBC) Count During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionGiga cells (GI)/L (Mean)
Basophils, Week 12Basophils, Week 24Eosinophils, Week 12Eosinophils, Week 24Lymphocytes, Week 12Lymphocytes, Week 24Monocytes, Week 12Monocytes, Week 24Platelet Count, Week 12Platelet Count, Week 24Total Neutrophils, Week 12Total Neutrophils, Week 24WBC Count, Week 12WBC Count, Week 24
APL + OBT-0.003-0.000-0.027-0.0100.5730.3730.0410.07947.84670.1430.9630.8611.5461.300

[back to top]

Change From Baseline in Haematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, White Blood Cell (WBC) Count During the Randomized Treatment Phase

Assessment was performed at Day 1, Week 12 and Week 24. Baseline was defined as the assessments done at Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Week 12 and 24) values. (NCT00197145)
Timeframe: Baseline (Day 1), Week 12 and Week 24

InterventionGiga cells (GI)/L (Mean)
Basophils, Week 12Eosinophils, Week 12Lymphocytes, Week 12Monocytes, Week 12Platelet Count, Week 12Total Neutrophils, Week 12WBC Count, Week 12
Placebo + OBT-0.0050.0900.050-0.095-3.500-0.935-0.900

[back to top]

Number of Participants With 50% Inhibitory Concentration (IC50) Fold Resistance at Baseline

The IC50 is a measure of the effectiveness of a substance in inhibiting a specific biological or biochemical function. IC50 was collected for abacavir (ABC), atazanavir (ATV), delavirdine (DLV), didanosine (DDI), efavirenz (EFV), emtricitabine, enfuvirtide , fosamprenavir (AMP), GW873140 (APL), indinavir (IDV), indinavir rooted with ritonavir (IDV/r), lamivudine, lopinavir rooted with ritonavir (LPV/r), nelfinavir (NFV), nevirapine (NVP), ritonavir (RTV), saquinavir (SQV), stavudine, tenofovir (TFV), tipranavir rooted with ritonavir (TPV/r), zidovudine (ZDV). Data is categorized for number of participants with each IC50 concentration of the individual drugs at Baseline (Day 1). (NCT00197145)
Timeframe: Baseline (Day 1)

,
InterventionParticipants (Count of Participants)
ABC < 4.5ABC >= 4.5ATV < 2.3ATV >= 2.3ATV/r < 5.2ATV/r >= 5.2DLV < 2.5DLV >= 2.5DDI < 1.3DDI >= 1.3EFV < 2.5EFV >= 2.5Emtricitabine < 3.5Emtricitabine >= 3.5Enfuvirtide < 2.5Enfuvirtide >= 2.5AMP < 2AMP >= 2APL < 2.5APL >= 2.5IDV < 2.1IDV >= 2.1IDV/r < 10IDV/r >= 10Lamivudine < 3.5Lamivudine >= 3.5LPV/r < 10LPV/r >= 10NFV < 2.5NFV >= 2.5NVP < 2.5NVP >= 2.5RTV < 2.5RTV >= 2.5SQV < 1.7SQV >= 1.7Stavudine < 1.7Stavudine >= 1.7TFV < 1.4TFV >= 1.4TPV/r < 4TPV/r >= 4ZDV < 1.9ZDV >= 1.9
APL + OBT013112112310013211013291121201122110133101121121121121124976112
Placebo + OBT47385647562938724790387447653829383856477338

[back to top] [back to top]

Number of Participants With Treatment Emergent Laboratory Abnormalities for Chemistry Data at Any Visit Post-Baseline

The participants with treatment emergent toxicities of laboratory abnormalities for chemistry data is reported . Participants with toxicities were categorized according to the division of AIDS (DAIDS) toxicity grading scale. Scale ranges from grade 1(mild)=symptoms causing no or minimal interference with usual social & functional activities, grade 2 (moderate)=symptoms causing greater than minimal interference with usual social & functional activities, grade 3 (severe)=symptoms causing inability to perform usual social & functional activities and grade 4 (potentially life threatening)=symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Scale ranges from 1-4, where higher grade reflects greater severity of symptoms. Baseline was defined as assessments done at Day 1. Only those parameters for which at least one value of toxicity grade was reported are summarized. (NCT00197145)
Timeframe: Up to Week 40

,
InterventionParticipants (Count of Participants)
Alanine Amino Transferase (ALT), Grade 1ALT, Grade 2Albumin, Grade 2Alkaline Phosphatase (ALP), Grade 1Aspartate Amino Transferase (AST), Grade 1AST, Grade 2Carbon Dioxide content/Bicarbonate (CO2), Grade 1Cholesterol, Grade 1Cholesterol, Grade 2Creatine Kinase (CK), Grade 1CK, Grade 2CK, Grade 3Creatinine, Grade 1Glucose, Grade 1Glucose, Grade 2Glucose, Grade 3Low Density lipoprotein (LDL) Cholesterol, Grade 2Lipase, Grade 1Lipase, Grade 2Potassium, Grade 4Sodium, Grade 1Total Bilirubin, Grade 1Total Bilirubin, Grade 2Total Bilirubin, Grade 4Triglycerides, Grade 2Triglycerides, Grade 3
APL + OBT01121120101213311310301101
Placebo + OBT10032031010023200001210020

[back to top]